CyFlow™ CD19 PE
Alternative Name: | B4 |
Antigen: | CD19 |
Application: | Flow cytometry |
Clonality: | monoclonal |
Clone: | LT19 |
Emission Maximum: | 576 nm |
Excitation Maximum: | 496 nm, 565 nm |
Field of Interest: | Immunophenotyping |
Format/Fluorochrome: | PE |
Isotype: | IgG1 |
Laser: | Blue , Green, Yellow |
Regulatory Status: | CE IVD |
Source Species: | Mouse |
Target Species: | Human |
Product number: | AM885461 |
CE IVD
HLDA Workshop | HCDM/HLDA 10 |
Concentration Unit | µg/mL |
Concentration | 40 |
Quantity | 100 tests |
Volume | 1.0 mL |
Immunogen | Daudi human Burkitt lymphoma cell line |
Background Information | CD19 is a transmembrane glycoprotein of Ig superfamily expressed by B cells from the time of heavy chain rearrangement until plasma cell differentiation. It forms a tetrameric complex with CD21 (complement receptor type 2), CD81 (TAPA-1) and Leu13. Together with BCR (B cell antigen receptor), this complex signals to decrease B cell treshold for activation by the antigen. Besides being signal-amplifying coreceptor for BCR, CD19 can also signal independently of BCR coligation and it turns out to be a central regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity. |
Antigen Distribution | CD19 (B4) is a 95 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed on B lymphocytes and follicular dendritic cells; it is lost on plasma cells. |
Usage | CE IVD usage Placeholder |
Storage Buffer | The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide and 0.2% (w/v) BSA. |
Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
Stability | Do not use after expiration date stamped on vial label. |
| Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF: CD19 amplifies B lymphocyte signal transduction by regulating Src‑family protein tyrosine kinase activation. J Immunol. 1999 Jun 15; 162(12):7088‑94. < PMID: 10358152 > | Inabe K, Kurosaki T: Tyrosine phosphorylation of B‑cell adaptor for phosphoinositide 3‑kinase is required for Akt activation in response to CD19 engagement. Blood. 2002 Jan 15; 99(2):584‑9. < PMID: 11781242 > | Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM: Strong cytosine‑guanosine‑independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J Immunol. 2003 Oct 1; 171(7):3697‑704. < PMID: 14500668 > | Lin CW, Liu TY, Chen SU, Wang KT, Medeiros LJ, Hsu SM: CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. Blood. 2005 Nov 15; 106(10):3567‑74. < PMID: 16046525 > | van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patiño PJ, van Dongen JJ, Franco JL: An antibody‑deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006 May 4; 354(18):1901‑12. < PMID: 16672701 > | Shi X, Xie C, Chang S, Zhou XJ, Tedder T, Mohan C: CD19 hyperexpression augments Sle1‑induced humoral autoimmunity but not clinical nephritis. Arthritis Rheum. 2007 Sep; 56(9):3057‑69. < PMID: 17763445 > | Stehlíková O, Chovancová J, Tichý B, Krejčí M, Brychtová Y, Panovská A, Francová Skuhrová H, Burčková K, Borský M, Loja T, Mayer J, Pospíšilová S, Doubek M: Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8‑color flow cytometry protocol in routine hematological practice. Int J Lab Hematol. 2014 Apr; 36(2):165‑71. < PMID: 24028768 >